JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Schrodinger Inc

Closed

SectorHealthcare

18.61 -3.17

Overview

Share price change

24h

Current

Min

18.51

Max

19.1

Key metrics

By Trading Economics

Income

-20M

-60M

Sales

-29M

60M

EPS

-0.64

Profit margin

-100.432

Employees

891

EBITDA

-32M

-51M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+54.87% upside

Market Stats

By TradingEconomics

Market Cap

-307M

1.5B

Previous open

21.78

Previous close

18.61

News Sentiment

By Acuity

70%

30%

343 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Schrodinger Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 lis 2024, 11:55 UTC

Top News

Schrödinger's Stock Soars 9% As It Enters Collaboration Pact With Novartis For Up To About $2.5 Billion In Payments -- MarketWatch

Peer Comparison

Price change

Schrodinger Inc Forecast

Price Target

By TipRanks

54.87% upside

12 Months Forecast

Average 29.75 USD  54.87%

High 35 USD

Low 19.5 USD

Based on 10 Wall Street analysts offering 12 month price targets forSchrodinger Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

7

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

23.27 / 26.13Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Very Strong Bullish Evidence

Sentiment

By Acuity

343 / 374 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.